Atea Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical organization dedicated to the discovery, development, and commercialization of oral antiviral treatments for individuals facing severe viral infections. Leveraging a proprietary nucleos(t)ide prodrug platform, the company strategically advances novel therapeutic candidates, particularly targeting single-stranded ribonucleic acid (ssRNA) viruses, which are known causes of serious viral diseases. Currently, Atea’s primary focus centers on the advancement of a combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). This regimen is progressing through a global Phase 3 development program, following positive Phase 2 results that demonstrated a 98% sustained virologic response at 12 weeks post-treatment with an eight-week duration. Atea secured exclusive worldwide rights to ruzasvir through a licensing agreement with Merck & Co. The company also maintains development efforts for bemnifosbuvir in the context of COVID-19, with a global Phase 3 trial (SUNRISE-3) having been initiated for high-risk non-hospitalized patients. Additionally, Atea has recently expanded its pipeline with a new development program targeting hepatitis E virus (HEV), specifically for immunocompromised patients. Earlier programs, such as AT-752 for dengue, were deprioritized in February 2023 to concentrate resources on the COVID-19 and HCV initiatives due to anticipated extensive clinical timelines and associated costs. Established in 2012, Atea Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
Atea Pharmaceuticals Q1 Earnings Call Highlights
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
Atea Pharmaceuticals (NASDAQ:AVIR) vs. Trevi Therapeutics (NASDAQ:TRVI) Financial Survey
Atea Pharmaceuticals Q4 Earnings Call Highlights
Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
BML Capital Management LLC Cuts Holdings in Atea Pharmaceuticals, Inc. $AVIR
Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4% – Here’s What Happened
Rapt Therapeutics (NASDAQ:RAPT) & Atea Pharmaceuticals (NASDAQ:AVIR) Head-To-Head Contrast